PFE
Income statement / Annual
Last year (2024), Pfizer Inc.'s total revenue was $63.63 B,
an increase of 6.84% from the previous year.
In 2024, Pfizer Inc.'s net income was $8.02 B.
See Pfizer Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$63.63 B |
$59.55 B |
$100.33 B |
$81.29 B |
$41.65 B |
$41.17 B |
$53.65 B |
$52.55 B |
$52.82 B |
$48.85 B |
| Cost of Revenue |
$21.78 B
|
$29.21 B
|
$38.24 B
|
$34.41 B
|
$11.77 B
|
$12.62 B
|
$16.01 B
|
$15.78 B
|
$15.95 B
|
$13.16 B
|
| Gross Profit |
$41.85 B
|
$30.34 B
|
$62.09 B
|
$46.88 B
|
$29.88 B
|
$28.55 B
|
$37.64 B
|
$36.77 B
|
$36.87 B
|
$35.69 B
|
| Gross Profit Ratio |
0.66
|
0.51
|
0.62
|
0.58
|
0.72
|
0.69
|
0.7
|
0.7
|
0.7
|
0.73
|
| Research and Development Expenses |
$10.74 B
|
$10.58 B
|
$11.43 B
|
$13.83 B
|
$9.40 B
|
$8.36 B
|
$7.97 B
|
$7.65 B
|
$7.84 B
|
$7.67 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.63 B
|
$14.47 B
|
$13.12 B
|
$12.25 B
|
$11.40 B
|
$12.67 B
|
$14.38 B
|
$14.73 B
|
$14.76 B
|
$14.73 B
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$25.36 B
|
$25.05 B
|
$24.54 B
|
$26.08 B
|
$20.80 B
|
$21.04 B
|
$22.35 B
|
$22.38 B
|
$22.60 B
|
$22.40 B
|
| Cost And Expenses |
$47.14 B
|
$54.26 B
|
$62.78 B
|
$60.50 B
|
$32.57 B
|
$33.66 B
|
$38.36 B
|
$38.16 B
|
$38.55 B
|
$35.56 B
|
| Interest Income |
$545.00 M
|
$1.62 B
|
$251.00 M
|
$36.00 M
|
$73.00 M
|
$225.00 M
|
$333.00 M
|
$391.00 M
|
$470.00 M
|
$471.00 M
|
| Interest Expense |
$3.09 B
|
$2.21 B
|
$1.24 B
|
$1.29 B
|
$1.45 B
|
$1.57 B
|
$1.32 B
|
$1.27 B
|
$1.19 B
|
$1.20 B
|
| Depreciation & Amortization |
$7.01 B
|
$6.29 B
|
$5.06 B
|
$5.19 B
|
$4.68 B
|
$5.80 B
|
$6.38 B
|
$6.27 B
|
$5.76 B
|
$5.16 B
|
| EBITDA |
$18.13 B |
$9.56 B |
$41.03 B |
$30.79 B |
$13.17 B |
$18.85 B |
$19.59 B |
$19.84 B |
$15.29 B |
$15.32 B |
| EBITDA Ratio |
0.28
|
0.16
|
0.41
|
0.38
|
0.32
|
0.46
|
0.37
|
0.38
|
0.29
|
0.31
|
| Operating Income Ratio |
0.26
|
0.09
|
0.37
|
0.26
|
0.22
|
0.18
|
0.28
|
0.27
|
0.27
|
0.27
|
| Total Other Income/Expenses Net |
-$8.46 B
|
-$4.23 B
|
-$2.82 B
|
$3.52 B
|
-$2.05 B
|
$3.97 B
|
-$3.40 B
|
-$2.09 B
|
-$5.92 B
|
-$4.33 B
|
| Income Before Tax |
$8.02 B
|
$1.06 B
|
$34.73 B
|
$24.31 B
|
$7.04 B
|
$11.49 B
|
$11.89 B
|
$12.31 B
|
$8.35 B
|
$8.97 B
|
| Income Before Tax Ratio |
0.13
|
0.02
|
0.35
|
0.3
|
0.17
|
0.28
|
0.22
|
0.23
|
0.16
|
0.18
|
| Income Tax Expense |
-$28.00 M
|
-$1.11 B
|
$3.33 B
|
$1.85 B
|
$370.00 M
|
$618.00 M
|
$706.00 M
|
-$9.05 B
|
$1.12 B
|
$1.99 B
|
| Net Income |
$8.02 B
|
$2.13 B
|
$31.37 B
|
$22.15 B
|
$9.16 B
|
$16.27 B
|
$11.15 B
|
$21.31 B
|
$7.22 B
|
$6.97 B
|
| Net Income Ratio |
0.13
|
0.04
|
0.31
|
0.27
|
0.22
|
0.4
|
0.21
|
0.41
|
0.14
|
0.14
|
| EPS |
1.4179 |
0.3755 |
5.5929 |
3.9539 |
1.6488 |
2.9219 |
1.8992 |
3.5685 |
1.18 |
1.1278 |
| EPS Diluted |
1.409 |
0.3712 |
5.471 |
3.8798 |
1.6262 |
2.8675 |
1.866 |
3.5168 |
1.17 |
1.1133 |
| Weighted Average Shares Out |
$5.66 B
|
$5.64 B
|
$5.61 B
|
$5.60 B
|
$5.56 B
|
$5.57 B
|
$5.87 B
|
$5.97 B
|
$6.09 B
|
$6.18 B
|
| Weighted Average Shares Out Diluted |
$5.70 B
|
$5.71 B
|
$5.73 B
|
$5.71 B
|
$5.63 B
|
$5.68 B
|
$5.98 B
|
$6.06 B
|
$6.16 B
|
$6.26 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
